PE79599A1 - Derivados de 5'-desoxicitidina - Google Patents

Derivados de 5'-desoxicitidina

Info

Publication number
PE79599A1
PE79599A1 PE1998000438A PE00043898A PE79599A1 PE 79599 A1 PE79599 A1 PE 79599A1 PE 1998000438 A PE1998000438 A PE 1998000438A PE 00043898 A PE00043898 A PE 00043898A PE 79599 A1 PE79599 A1 PE 79599A1
Authority
PE
Peru
Prior art keywords
refers
desoxi
group
compound
formula
Prior art date
Application number
PE1998000438A
Other languages
English (en)
Inventor
Nobuo Shimma
Kazuo Hattori
Tohru Ishikawa
Yasunori Kohchi
Hitomi Suda
Nobuhiro Oikawa
Hideo Ishitsuka
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE79599A1 publication Critical patent/PE79599A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I), DONDE R1 ES H O UN GRUPO FACILMENTE HIDROLIZABLE; R2 ES H o -CO-OR4, R4 ES UN GRUPO HIDROCARBONADO C1-C15 SATURADO O INSATURADO O UN GRUPO DE FORMULA -(CH2)nY; "Y" ES CICLOHEXILO O FENILO; n ES 0-4; R3 ES H, Br, I, CN, ALQUILO C1-C4 OPCIONALMENTE SUSTITUIDO CON HALOGENO, ENTRE OTROS. CUANDO R2 ES H, R3 NO ES H. SON COMPUESTOS PREFERIDOS 5`-DESOXI-5-ETINILCITIDINA; 5'-DESOXI-5-PROP-1-INILCITIDINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ADEMAS 3 Y 5 FLUORURACILO DE PREFERENCIA 5-FLUORO-1-(2-TETRAHIDROFURIL)URACILO, 1-(n-HEXILOXICARBONIL)-5-FLUORURACILO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO PARA LA PREPARACION. EL COMPUESTO I PUEDE SER UTIL PARA TRATAR TUMORES
PE1998000438A 1997-06-02 1998-06-01 Derivados de 5'-desoxicitidina PE79599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97108791 1997-06-02

Publications (1)

Publication Number Publication Date
PE79599A1 true PE79599A1 (es) 1999-08-25

Family

ID=8226859

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000438A PE79599A1 (es) 1997-06-02 1998-06-01 Derivados de 5'-desoxicitidina

Country Status (33)

Country Link
US (2) US6114520A (es)
JP (1) JP3081185B2 (es)
KR (1) KR100312899B1 (es)
CN (1) CN1197871C (es)
AR (1) AR012878A1 (es)
AT (1) ATE440854T1 (es)
AU (1) AU746170B2 (es)
BR (1) BR9801744A (es)
CA (1) CA2237368C (es)
CO (1) CO4940436A1 (es)
CZ (1) CZ295706B6 (es)
DE (2) DE69841086D1 (es)
ES (2) ES2329428T3 (es)
FR (1) FR2763953B1 (es)
GB (1) GB2325931B (es)
HR (1) HRP980290A2 (es)
HU (1) HU227852B1 (es)
ID (1) ID19801A (es)
IL (1) IL124661A0 (es)
IT (1) ITMI981196A1 (es)
MA (1) MA26503A1 (es)
MY (1) MY128985A (es)
NO (1) NO316609B1 (es)
NZ (1) NZ330360A (es)
PE (1) PE79599A1 (es)
PL (1) PL192832B1 (es)
RS (1) RS50010B (es)
RU (1) RU2238278C2 (es)
SA (1) SA98190103B1 (es)
SG (1) SG66466A1 (es)
TR (1) TR199800988A3 (es)
TW (1) TW584636B (es)
ZA (1) ZA984478B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
DE60013957T2 (de) * 1999-05-26 2006-02-23 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von Vinylpyrimidinderivaten
US6906182B2 (en) 2000-12-01 2005-06-14 Cell Works Therapeutics, Inc. Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use
AU2005311730B2 (en) * 2004-12-03 2011-11-17 Adherex Technologies, Inc. Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
US20060161076A1 (en) * 2005-01-06 2006-07-20 Diamics, Inc. Systems and methods for collection of cell clusters
US20060189893A1 (en) * 2005-01-06 2006-08-24 Diamics, Inc. Systems and methods for detecting abnormal cells
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
WO2009082846A1 (fr) * 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
CN101469008B (zh) * 2007-12-29 2013-08-07 上海特化医药科技有限公司 卡培他滨羟基衍生物、其制备方法和用于制备卡培他滨
WO2009094847A1 (fr) * 2007-12-28 2009-08-06 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de capécitabine, procédés de préparation et d' utilisation de la capécitabine
WO2009082844A1 (fr) * 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
EP2276774B1 (en) 2008-03-14 2016-08-17 Retrotope, Inc. Therapeutic substances that modulate genome methylation
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
EP2488182B1 (en) * 2009-10-14 2017-07-19 Elion Oncology LLC Treating neurotoxicity associated with combinations of 5-FU or its prodrugs and DPD inhibitors
CN104926890B (zh) * 2015-06-04 2018-04-03 新乡学院 一种1,2‑o‑二乙酰基‑3,5‑o‑二苯甲酰基核糖的合成方法
BR112020015745A2 (pt) 2018-02-02 2020-12-08 Maverix Oncology, Inc. Conjugados de fármacos de moléculas pequenas de monofosfato de gemcitabina
CN113321694A (zh) * 2021-06-22 2021-08-31 药康众拓(江苏)医药科技有限公司 N4-羟基胞苷衍生物及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5726278B2 (es) * 1973-03-13 1982-06-03
GB1561290A (en) * 1975-10-16 1980-02-20 Nyegaard & Co As Pyrimid - 2 - ones
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
US4328229A (en) * 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
JPS5677226A (en) * 1979-11-27 1981-06-25 Taiho Yakuhin Kogyo Kk Antitumorigenic agent
JPS61500224A (ja) * 1983-10-26 1986-02-06 グリ−ル、シエルダン　ビ− 腫瘍性組織を放射線に対して増感する医薬組成物
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
GB9020930D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
JP2614164B2 (ja) * 1991-05-27 1997-05-28 大鵬薬品工業株式会社 抗腫瘍効果増強のための及び腫瘍治療のための組成物
DE4123520A1 (de) * 1991-07-16 1993-01-21 Inst Molekularbiologie Ak Mittel zur regeneration des blutbildes durch foerderung der leukozytenproliferation
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU6081294A (en) * 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
HUT73414A (en) * 1993-09-14 1996-07-29 Merrell Pharma Inc 5-(1-fluoro-vinyl)-1h-pyrimidine-2,4-dione derivatives useful as antineoplastic agents
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
WO1996037214A2 (en) * 1995-05-26 1996-11-28 F. Hoffmann-La Roche Ag Compositions of interleukin and pyrimidine nucleosides

Also Published As

Publication number Publication date
PL326604A1 (en) 1998-12-07
KR19990006547A (ko) 1999-01-25
DE19823484A1 (de) 1998-12-03
AU6798598A (en) 1998-12-03
ATE440854T1 (de) 2009-09-15
CN1197871C (zh) 2005-04-20
ES2142763B1 (es) 2001-04-01
NZ330360A (en) 1999-03-29
FR2763953A1 (fr) 1998-12-04
JPH10330395A (ja) 1998-12-15
CZ295706B6 (cs) 2005-10-12
HU227852B1 (en) 2012-05-02
ES2329428T3 (es) 2009-11-25
NO982473D0 (no) 1998-05-29
AU746170B2 (en) 2002-04-18
SA98190103B1 (ar) 2006-04-18
FR2763953B1 (fr) 2005-01-07
RS50010B (sr) 2008-09-29
HUP9801256A3 (en) 2004-03-01
GB2325931A (en) 1998-12-09
PL192832B1 (pl) 2006-12-29
SG66466A1 (en) 1999-07-20
RU2238278C2 (ru) 2004-10-20
NO316609B1 (no) 2004-03-08
NO982473L (no) 1998-12-03
HU9801256D0 (en) 1998-07-28
US6114520A (en) 2000-09-05
DE69841086D1 (de) 2009-10-08
TW584636B (en) 2004-04-21
IL124661A0 (en) 1998-12-06
CN1201037A (zh) 1998-12-09
YU22598A (sh) 2001-12-26
HRP980290A2 (en) 1999-04-30
ID19801A (id) 1998-08-06
CZ167598A3 (cs) 1998-12-16
TR199800988A2 (xx) 1998-12-21
ZA984478B (en) 1998-12-02
ITMI981196A1 (it) 1999-11-29
GB9811762D0 (en) 1998-07-29
US6211166B1 (en) 2001-04-03
TR199800988A3 (tr) 1998-12-21
CO4940436A1 (es) 2000-07-24
JP3081185B2 (ja) 2000-08-28
HUP9801256A2 (hu) 1999-05-28
CA2237368A1 (en) 1998-12-02
MY128985A (en) 2007-03-30
GB2325931B (en) 2001-07-25
CA2237368C (en) 2009-03-03
KR100312899B1 (ko) 2002-03-08
BR9801744A (pt) 2000-03-21
ES2142763A1 (es) 2000-04-16
AR012878A1 (es) 2000-11-22
MA26503A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
PE79599A1 (es) Derivados de 5'-desoxicitidina
KR960014121A (ko) 아로일-피페리딘 유도체
AR005706A1 (es) Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico
AR012660A1 (es) Uso de compuestos de quinazolina para la manufactura de un medicamento util para el tratamiento de enfermedades poliquisticas del rinon.
KR880000400A (ko) 융합된 사이클릭 아제핀-2-온 유도체 및 그의 제조방법
ES2059313T3 (es) Peptidilaminodioles.
KR950005308A (ko) 직장투여용 조성물
KR870003974A (ko) 비시클로 치환된 페닐아세토니트릴 유도체
EA199800909A1 (ru) Тригидрат мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)пиперазин-1-ил)этил)-6-хлор-1,3-дигидро-2н-индол-2-она, фармацевтическая композиция и способ лечения психического расстройства
CO5040216A1 (es) Agonistas de adenosina a 1, proceso para su preparacion y composiciones farmaceuticas que los contienen
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
ES2173172T3 (es) Derivados de 1,3-dihidroindol-2-ona sustituidos en 3 por un grupo nitrogenado como agonistas y/o antagonistas de la vasopresina y/o de la octocina.
PT99436A (pt) Processo para a preparacao de derivados de amino-sulfonil-carbamatos e de com- posicoes farmaceuticas que os contem
KR880009922A (ko) 프롤리날 유도체
PE20001084A1 (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas
KR960010635A (ko) 약제학적 화합물
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
CS621987A2 (en) Coating composition
CO5180605A1 (es) Compuestos de indol
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
KR920701120A (ko) 치환된 비시클로헵탄디온 유도체
KR890006639A (ko) 벤조티아진 디옥사이드 유도체
ATE44648T1 (de) Antihypertensives kombinationspraeparat.
KR900012903A (ko) 피롤리딘 화합물 및 약제학적 용도

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed